A genome-wide association study identifies novel and functionally related susceptibility Loci for Kawasaki disease

David Burgner1, Sonia Davila, Willemijn B Breunis

  • 1School of Pediatrics and Child Health, University of Western Australia, Perth, Australia.

Plos Genetics
|January 10, 2009
PubMed

Insights

Genetic factors influence Kawasaki disease (KD) susceptibility. This genome-wide association study identified novel gene variants, including NAALADL2 and ZFHX3, linked to KD risk and potential cardiovascular implications.

Area of Science:

  • Genetics
  • Immunology
  • Pediatrics

Background:

  • Kawasaki disease (KD) is a critical pediatric vasculitis affecting coronary arteries.
  • Genetic susceptibility combined with environmental triggers, likely infections, is implicated in KD pathogenesis.
  • Untreated KD carries significant risks of coronary artery damage.

Purpose of the Study:

  • To identify genetic determinants of Kawasaki disease susceptibility using genome-wide association studies (GWAS).
  • To replicate and fine-map associated genetic variants in independent cohorts.
  • To explore the functional relationships and transcript levels of identified genes in KD patients.

Main Methods:

  • Genome-wide association study (GWAS) in Caucasian KD cases and controls.
  • Replication in an independent cohort of KD families.
  • Fine-mapping of associated variants and pathway analysis.
  • Measurement of blood transcript levels for associated genes during acute and convalescent KD.

Main Results:

  • Significant associations were found for 40 single nucleotide polymorphisms (SNPs) and six haplotypes, implicating 31 genes.
  • NAALADL2 and ZFHX3 showed the most significant associations after combined analysis.
  • Fine-mapping identified stronger associations in neighboring regions for several genes, including ZFHX3 and NAALADL2.
  • A functional network involving LNX1, CAMK2D, ZFHX3, CSMD1, and TCP1 was identified, related to inflammation and cardiovascular pathology.
  • Reduced transcript levels of fine-mapped genes were observed during acute KD.

Conclusions:

  • Novel genetic variants associated with Kawasaki disease susceptibility have been identified.
  • The identified genes and their functional network offer insights into KD pathogenesis.
  • These findings may have implications for understanding other cardiovascular diseases.

Related Concept Videos

Single Nucleotide Polymorphisms-SNPs01:05

Single Nucleotide Polymorphisms-SNPs

A single nucleotide polymorphism or SNP is a single nucleotide variation at a specific genomic position in a large population. It is the most prevalent type of sequence variation found in the human genome. Point mutations that occur in more than 1% of the population qualify as SNPs. These are present once every 1000 nucleotides on an average in the human genome. Replacement of a purine with another purine (A/G) or a pyrimidine with another pyrimidine (C/T) is known as a transition. In contrast,...
Genome-wide Association Studies-GWAS01:11

Genome-wide Association Studies-GWAS

Genome-wide association studies or GWAS are used to identify whether common SNPs are associated with certain diseases. Suppose specific SNPs are more frequently observed in individuals with a particular disease than those without the disease. In that case, those SNPs are said to be associated with the disease. Chi-square analysis is performed to check the probability of the allele likely to be associated with the disease.
GWAS does not require the identification of the target gene involved in...
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...